Ultrasmall Downconverting Nanoparticle for Enhanced Cerenkov Imaging.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 33950695.
- Also identified by DOI 10.1021/acs.nanolett.1c00049 and PMC identifier 8879088.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cerenkov imaging provides an opportunity to expand the application of approved radiotracers and therapeutic agents by utilizing them for optical approaches, which opens new avenues for nuclear imaging. The dominating Cerenkov radiation is in the UV/blue region, where it is readily absorbed by human tissue, reducing its utility <i>in vivo</i>. To solve this problem, we propose a strategy to shift Cerenkov light to the more penetrative red-light region through the use of a fluorescent down-conversion technique, based upon europium oxide nanoparticles. We synthesized square-shape ultrasmall Eu<sub>2</sub>O<sub>3</sub> nanoparticles, functionalized with polyethylene glycol and chelate-free radiolabeled for intravenous injection into mice to visualize the lymph node and tumor. By adding trimethylamine N-oxide during the synthesis, we significantly increased the brightness of the particle and synthesized the (to-date) smallest radiolabeled europium-based nanoparticle. These features allow for the exploration of Eu<sub>2</sub>O<sub>3</sub> nanoparticles as a preclinical cancer diagnosis platform with multimodal imaging capability.
Medical subject headings
- Europium
- Nanoparticles